The Government plans to offer additional compensation to general practitioners (GPs) who help identify patients most requiring weight loss injections. A £25 million funding allocation will enable doctors to prescribe appetite-suppressing shots for severely obese individuals in conjunction with weight management support under the new GP contract.

Roughly 2.4 million Britons are currently using weight-loss injections like Mounjaro and Wegovy, primarily through private payment. These once-weekly injections, intended for severely obese individuals with multiple health issues, are expected to become accessible through the NHS.

Health Secretary Wes Streeting emphasized the importance of equitable access to weight-loss drugs based on necessity rather than financial capacity. The initiative aims to address the prevalence of dangerous unlicensed drugs being distributed by unauthorized prescribers due to limited NHS provision.

Healthcare leaders have cautioned that if all eligible patients sought Mounjaro within a year, it could strain primary care services. To alleviate GP workload, Henry Gregg from the National Pharmacy Association suggested utilizing pharmacies for prescription services, highlighting the slow progress in NHS weight loss treatment distribution.

Injections like Ozempic, Wegovy, and Mounjaro mimic the GLP-1 hormone to reduce hunger and slow digestion, aiding weight loss. While effective, these injections should be complemented with personalized diet, exercise, and lifestyle guidance to prevent weight regain and minimize side effects.

The Obesity Health Alliance, representing 60 health organizations, expressed concerns over the NHS’s limited capacity to expand the distribution of transformative weight-loss injections. Although the NHS announced the rollout of Mounjaro with enthusiasm, subsequent investigations revealed rationing and slow progress in meeting demand.

Despite the eligibility of millions for weight-loss injections, insufficient funding has hindered the planned phased rollout. Yearly targets for prescription doses have fallen short, raising challenges in providing adequate support to the growing number of patients seeking obesity interventions.